drugset / Trial / NCT01254578
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
NaSingle-groupOpen-labelTreatment
Summary
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.
Timeline
- Start
- 2010-11-24
- Primary completion
- 2012-11-09
- Completion
- 2012-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
Indications
Burkitt lymphoma
MALT lymphoma
Richter transformation
T-cell large granular lymphocyte leukemia
Waldenstrom macroglobulinemia
acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent
acute myeloid leukemia with t(9;11)(p22;q23)
acute myeloid leukemia, inv(16)(p13.1;q22)
acute myeloid leukemia, t(16;16)(p13.1;q22)
acute myeloid leukemia, t(8;21)(q22; q22.1)
acute promyelocytic leukemia
adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
chronic lymphocytic leukemia/small lymphocytic lymphoma
extranodal nasal NK/T cell lymphoma
grade III lymphomatoid granulomatosis
hepatosplenic T-cell lymphoma
intraocular lymphoma
large-cell immunoblastic lymphoma
mantle cell lymphoma
mycosis fungoides and variants
nodal marginal zone B-cell lymphoma
post-transplant lymphoproliferative disease
primary cutaneous B-cell lymphoma
prolymphocytic leukemia
refractory hairy cell leukemia
small intestine lymphoma
splenic marginal zone lymphoma
testicular lymphoma